ISSN: 1170-7690

Journal Home

Journal Guideline

PharmacoEconomics Q1 Unclaimed

Adis International Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

PharmacoEconomics is a journal indexed in SJR in Pharmacology and Public Health, Environmental and Occupational Health with an H index of 118. It has a price of 3290 €. It has an SJR impact factor of 1,517 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,517.

PharmacoEconomics focuses its scope in these topics and keywords: cost, treatment, effectiveness, model, healthcare, economic, review, patients, development, england, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Health Policy (Q1) Pharmacology (Q1) Public Health, Environmental and Occupational Health (Q1)

Price

3290 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,517

SJR Impact factor

118

H Index

106

Total Docs (Last Year)

332

Total Docs (3 years)

5784

Total Refs

1361

Total Cites (3 years)

286

Citable Docs (3 years)

3.88

Cites/Doc (2 years)

54.57

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Pharmacological Reviews Q1
Drug Resistance Updates Q1
Annual Review of Pharmacology and Toxicology Q1
Molecular Therapy Q1
Journal for ImmunoTherapy of Cancer Q1

Compare this journals

Aims and Scope

Best articles by citations

Willingness to Pay for a QALY

Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France

A Review of the Pharmacoeconomics of Pharmaceutical Care

The Effects of Type 1 Diabetes and its Long-Term Complications on Physical and Mental Health Status

Complex Valuation: Applying Ideas from the Complex Intervention Framework to Valuation of a New Measure for End-of-Life Care

Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment

Productivity Costs in Health-State Valuations

Advances in Cancer Therapeutics and Patient Access to New Drugs

Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer???s Disease

Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic Evaluation

Does 'NICE blight' exist, and if so, why?

Contributors

SHOW MORE ARTICLES

Is the Childhood Asthma Questionnaire a Good Measure of Health-Related Quality of Life of Asthmatic Children in Asia?

Essentials of Pharmacoeconomics

Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?

Authors' Reply to Gandjour: "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines"

The Lifetime Cost of Bipolar Disorder in the US

Economic Evaluation of Pioglitazone Hydrochloride in the Management of Type 2 Diabetes Mellitus in Canada

A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models

Effects of Reference Pricing in Pharmaceutical Markets

Single Technology Appraisals by NICE

Economic and Developmental Considerations for Pharmacogenomic Technology

Economic Evaluation of Weekly Epoetin Alfa versus Biweekly Darbepoetin Alfa for Chemotherapy-Induced Anaemia

Reduce Mortality Risk Above All Else: A Discrete-Choice Experiment in Acute Coronary Syndrome Patients